Enfield Exploration Corp. Completes Share Consolidation

VANCOUVER, B.C. — October 29, 2026 — Leads & Copy — Enfield Exploration Corp. has completed a consolidation of its common shares on a one-for-two basis, reducing the number of issued and outstanding shares. This corporate action aligns with the company's business combination transaction with Xerient Pharma Ltd.

Prior to the share consolidation, Enfield Exploration Corp. had 13,680,695 shares issued and outstanding. Following the consolidation, the company now has approximately 6,840,361 shares outstanding. The consolidation ratio was applied proportionally to adjust the exercise or conversion prices, as well as the number of shares issuable under the company's outstanding convertible securities, stock options, and warrants.

The record date for the consolidation was October 28, 2026. The company's name remains unchanged, and the post-consolidation shares have been assigned a new CUSIP number, 292755303. This consolidation was approved by the company's board of directors, adhering to the company's articles.

Registered shareholders will receive a letter of transmittal containing instructions on how to exchange their existing share certificates for Direct Registration Advice (DRS) representing the consolidated shares they are entitled to. Shareholders who hold their shares through an intermediary, known as non-registered shareholders, are not required to take any action to effect the consolidation.

Enfield Exploration Corp. is an unlisted reporting issuer focused on identifying strategic mergers and acquisition opportunities. The company aims to create long-term shareholder value through disciplined growth and responsible operations.

Source: Enfield Exploration Corp.